Introduction

ReLIA Biotechnologies (Jiangsu), Inc. is a wholly-owned subsidiary of ReLIA Diagnostic Systems, USA. The company was founded in China Medical City (CMC), Taizhou, China in 2010, with registered capital of 2.3 million USD and total investment of 4.6 million USD.

ReLIA Diagnostic Systems has developed a low-cost, high-performance portable immunoassay system for point-of-care (POC) diagnosis that provides high sensitivity, precision, accuracy and reliability of expensive and complex central laboratory systems, with the advantage of bedside testing.

Its state-of-art manufacturing facility has received GMP certification from Chinese SFDA for manufacturing medical device and diagnostic reagent products. It also provides market with products that CE-marked.


一、公司簡介
瑞萊生物科技（江蘇）有限公司是美國著名的ReLIA生物醫(yī)療診斷公司在中國的獨(dú)資企業(yè)，于2010年在江蘇泰州中國醫(yī)藥城成立，注冊(cè)資金230萬美元，投資總額超過460萬美元。
瑞萊公司主要從事體外診斷試劑，特別是即時(shí)檢驗(yàn)技術(shù)（POCT）產(chǎn)品的研發(fā)、生產(chǎn)及銷售，研制開發(fā)出具有國際自主知識(shí)產(chǎn)權(quán)的ReLIA 多功能免疫檢測系統(tǒng)。現(xiàn)公司已經(jīng)獲得：國家食品藥品監(jiān)督管理局(SFDA)頒發(fā)的《醫(yī)療器械生產(chǎn)許可證》、歐盟的CE認(rèn)證，公司最終將通過美國的FDA認(rèn)證。
ReLIA 多功能免疫檢測系統(tǒng)具備了“快速、定量、全血檢測、使用簡便”等即時(shí)檢驗(yàn)技術(shù)的必備條件，是國內(nèi)率先擁有國際自主知識(shí)產(chǎn)權(quán)的POCT技術(shù)產(chǎn)品。